At the University Medical Center Hamburg-Eppendorf (UKE) there are new possibilities for cancer therapy: The Center for Personalized Medicine-Oncology (ZPM-O) of the University Cancer Center Hamburg (UCCH), as a member of the "German Network for Personalized Medicine" (DNPM), offers customized diagnostics and therapy. As a result of special quality standards, the ZPM-Oncology of the UCCH was successfully certified according to the strict OnkoZert criteria of the German Cancer Society. ZPM-Oncology is the first certified facility of its kind in Northern Germany.

A novel combination of four drugs has significantly improved the prognosis of patients with high-risk myeloma, a malignant disease of the bone marrow. A clinical study initiated at the UCCH, in which 20 German treatment centers participated, showed that almost 80 percent of patients up to 70 years of age and more than 60 percent of patients over 70 years of age were still relapse-free two years after completion of therapy. For a long time, the median survival time of high-risk myeloma patients was only about two years. The UKE scientists have now published the study results in the Journal of Clinical Oncology.

In the annual ranking of the U.S. magazine "Newsweek" on the international 300 best oncology institutions, the treatment quality of the University Cancer Center Hamburg is also shown in an international comparison. In the 2024 list compiled with the support of the data portal Statista, the UCCH is ranked 23rd and has risen another 10 places compared to the previous year.

Representatives of the newly founded Comprehensive Cancer Center Mecklenburg-Vorpommern at the Rostock and Greifswald sites visited the UCCH: The focus was on the exchange of networks and best practice models.